Ascendiant Capital Reiterates Rating on OTLK $OTLK
Key Points
- Ascendiant Capital now rates Outlook Therapeutics, Inc. ($OTLK) "buy" with a $10 target.
- Ascendiant Capital's $10 price target implies 796.86% upside from Outlook Therapeutics, Inc.'s ($OTLK) current $1.11 share price.
- The Street's average $OTLK price target is $4.90 (Strong Buy).
- $OTLK last traded around $1.11.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Ascendiant Capital reiterated its rating on Outlook Therapeutics, Inc. ($OTLK) to a "buy" rating in a recent research note and set a price target of $10, a 796.86% upside from the current price.
Outlook Therapeutics, Inc. Stock Up 72.9%
Shares of Outlook Therapeutics, Inc. ($OTLK) traded around $1.11 on Saturday, up 72.9% for the day.
Outlook Therapeutics, Inc. Earnings
Analysts Set New Price Targets
About Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Get Outlook Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $OTLK, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.